UBS O'Connor’s MiNK Therapeutics INKT Stock Holding History

UBS O'Connor’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,159	Closed	-$25.3K	–	557
2023 Q3	$25.3K	Hold	2,159	–	–	﹤0.01%	506
2023 Q2	$45.3K	Buy	+2,159	New	+$43.3K	﹤0.01%	508

Other funds holding INKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS O'Connor's INKT Position: Q4 2023 in Review

UBS O'Connor sold out of MiNK Therapeutics (INKT) in Q4 2023, closing a stake of 2,159 shares — an estimated $25.3K sold.

UBS O'Connor first reported a position in INKT in Q2 2023 and held it in 2 quarters. The position peaked at $45.3K in Q2 2023. 34 funds tracked by Wall St. Rank hold INKT as of Q4 2023.

UBS O'Connor reported no remaining MiNK Therapeutics position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 2,159 MiNK Therapeutics shares in Q4 2023, an estimated $25.3K.
UBS O'Connor first reported a position in MiNK Therapeutics in Q2 2023 and held it in 2 quarters.
UBS O'Connor's MiNK Therapeutics position peaked at $45.3K in Q2 2023.
34 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.